#Japan #Tokyo #gene therapy #Fujifilm #HORIBA

Fujifilm and Horiba Collaborate on Gene Therapy Production

Fujifilm Corporation, headquartered in Minato-ku, Tokyo, and Horiba Ltd., based in South Kyoto, have announced their collaboration to develop a cutting-edge gene delivery device. This exciting initiative aims to significantly improve the productivity of gene therapy drugs, achieving approximately a 100-fold increase compared to conventional methodologies. This innovation utilizes continuous electroporation technology, enabling the efficient introduction of genes into cells, which is crucial in the biopharmaceutical sector.

The Significance of Gene Therapy

Gene therapy represents a revolutionary approach to treating diseases at their genetic root, by correcting malfunctioning genes that cause illnesses. This biopharmaceutical is gaining traction as a potential cure for various serious diseases, particularly where effective treatment options are currently absent. Global anticipation surrounding gene therapies has spiked, with a projected annual market growth rate of roughly 30% by 2030. However, significant hurdles remain, including the complexity and inefficiency surrounding current manufacturing processes and the associated R&D costs.

To address these challenges, Fujifilm and Horiba have combined their expertise to develop a device that enhances the productivity and reduces the manufacturing costs of gene therapies. The joint project began in 2023, leveraging Fujifilm's comprehensive process control technology and advanced know-how in biopharmaceuticals, along with Horiba's extensive manufacturing experience and global support network.

Highlights of the Continuous Electroporation Device

Effective gene delivery into cultured cells is critical for improving the production efficiency of gene therapies. Traditional methods for introducing genes into cells typically use chemical reagents, which present challenges in controlling complex chemical reactions and interactions between cells and substances. The continuous electroporation technology developed by Fujifilm represents a breakthrough, utilizing controlled voltage to create tiny pores in cell membranes, thereby allowing direct gene injection with high efficiency.

Moreover, the continuous flow system enables adjustment of production volumes ranging from small to large scale. This innovation leads to approximately 100 times higher productivity in manufacturing gene therapies compared to traditional batch processing approaches. The successful implementation of this device is expected to substantially contribute to enhancing production efficiency and lowering costs in gene therapy manufacturing.

Commitment to Addressing Unmet Medical Needs

Fujifilm and Horiba are committed to leveraging their strengths to tackle social challenges, particularly in the context of unmet medical needs. Gene therapies aim to address diseases that currently lack effective treatments, thus contributing to the development of healthcare solutions that can significantly improve patient outcomes.

Fujifilm's Executive Officer, Yoshihisa Iida, stressed the company's dedication to supporting pharmaceutical companies and patients from the initial development stages to commercial production. He indicated that the continuous electroporation technology can significantly help improve gene delivery efficiency and reduce manufacturing costs. By integrating Fujifilm's existing technologies with Horiba's manufacturing prowess, the two companies aspire to enhance access to gene therapies for patients in need.

Horiba's President, Masayuki Adachi, expressed enthusiasm for the collaborative effort, emphasizing the importance of growth in the Bio-Healthcare sector for the company's future expansion. With a strong background in high-volume production process efficiency, Horiba is committed to utilizing its analytical and measurement technologies to facilitate the practical implementation of this device, supporting better health and quality of life for people worldwide.

Looking Forward

The alliance between Fujifilm and Horiba not only signifies an important step in biotechnology innovation but also represents a strategic move to improve healthcare solutions worldwide. With a shared vision to address pressing medical challenges, both companies are poised to play a crucial role in the advancement of gene therapy and the continuous growth of the biotech landscape.

For more information about Fujifilm and Horiba, visit their official websites. Their groundbreaking collaboration paves the way towards a healthier future, driven by technology and innovation.